Basic premises: searching for new targets and strategies in diffuse gliomas

Sansone, Giulio; Vivori, Nicolò; Vivori, Christian; Pïcca, Alberto

doi:10.1007/s40336-022-00507-7

Cited by 2 publications

(3 citation statements)

References 187 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A crucial question for the effective clinical translation of any novel candidate target alteration is its frequency in the cancer cell population, thus discriminating between clonal and subclonal events [57]. In fact, GBM is typically characterized by a formidable degree of subclonal heterogeneity [58], with neighboring cells displaying activation of different RTKs [59].…”

Section: F3t3 As a Theranostic Marker?mentioning

confidence: 99%

Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives

Picca,

Sansone,

Santonocito

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

In 2012, whole-transcriptome sequencing analysis led to the discovery of recurrent fusions involving the FGFR3 and TACC3 genes as the main oncological driver in a subset of human glioblastomas. Since then, FGFR3-TACC3 fusions have been identified in several other solid cancers. Further studies dissected the oncogenic mechanisms of the fusion protein and its complex interplay with cancer cell metabolism. FGFR3-TACC3 fusion-driven gliomas emerged as a defined subgroup with specific clinical, histological, and molecular features. Several FGFR inhibitors were tested in FGFR3-TACC3 fusion-positive gliomas and proved some efficacy, although inferior to the results seen in other FGFR3-TACC3 fusion-driven cancers. In this review, we summarize and discuss the state-of-the-art knowledge resulting from a 10-year research effort in the field, its clinical implications for glioma patients, the potential reasons for targeted therapy failures, and the perspective of emerging treatments.

show abstract

Section: F3t3 As a Theranostic Marker?mentioning

confidence: 99%

Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives

Picca,

Sansone,

Santonocito

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…The present issue of Clinical and Translational Imaging focuses on the clinical implications and the changes in daily practice occurring as a result of the growing use of advanced neuroimaging modalities. As finely depicted by the articles of this issue, all the steps of patient care are being transformed by the availability of advanced neuroimaging, including (1) prognostic assessment [1], (2) multidisciplinary discussion [2], (3) planning and performing surgery [3][4][5], (4) response assessment after cytotoxic or targeted treatments [6][7][8], and (5) the identification of new therapeutic strategies [9] (Fig. 1).…”

mentioning

confidence: 99%

“…Despite all therapeutic measures, the overall survival of malignant gliomas remains poor, the identification of alternative strategies being long overdue. Immunotherapies directed at uplifting the state of local immune suppression by targeting the tumor microenvironment are currently being experimented in the context of clinical trials [9]. By helping to define immune cell infiltration, radiomics [9] and immuno-PET [3] studies might represent a fine complement for patient selection and longitudinal monitoring in immune therapy trials, encouraging research in this area.…”

mentioning

confidence: 99%